| Period | Completed events | Price coverage | Hit rate | Median excess return | Average excess return | Worst excess return |
|---|---|---|---|---|---|---|
| 5D | 5Developing evidence | 100.0% (5/5) | 60.0% (3/5) | +0.0% | +1.4% | -4.6% |
| 20D | 4Small sample | 100.0% (4/4) | 25.0% (1/4) | -1.9% | -0.5% | -4.1% |
| 60D | 3Small sample | 100.0% (3/3) | 33.3% (1/3) | -4.4% | -0.5% | -12.7% |
| 120D | 2Small sample | 100.0% (2/2) | 50.0% (1/2) | -2.1% | -2.1% | -9.4% |
COMPANY RESEARCH
GENOWAY
ALGEN.PA · France · Healthcare · Biotechnology
INSIDER SIGNAL
Insider activity score：52.9 / 100
2 insiders · 5 purchase events · €324k net purchases
Europe #511 · France #46
WHY THIS SIGNAL?
Score anatomy
Each bar shows the contribution to the current score; the weights and formula stay unchanged.
Cluster+10.5 / 35
How many distinct insiders bought in the cluster
Purchase size+20.6 / 25
Purchase value relative to company size and liquidity
Role+13.0 / 20
The seniority and relevance of participating insiders
Recency+6.2 / 10
How recently the purchases occurred
Conviction+8.7 / 10
How clearly buying stands out from other activity
What is holding the score back?
- ⚠ Buyer breadth is moderate · fewer than 4 distinct filers
- ⚠ Insider role contributes less on the current role scale
- ⚠ Purchase activity is becoming less recent
The role contribution uses the inverted role input of the current European model.
Buying concentration
97%
Largest buyer：Alexandre Fraichard · 370k EUR
Gross qualified purchase transaction-line value：382k EUR
The headline € total is net buying for the screen; this module uses gross qualified purchase transaction-line values in the filing currency, so the amounts can differ. The current 15-day buyer-breadth input counts distinct buyers; value concentration is disclosed separately here.
This is a ranking under the current European screening rules—not a probability of gain, return forecast, or buy recommendation.
Key purchase quotes (filing currency)
| Filer | Price per unit | Trade date |
|---|---|---|
| Alexandre Fraichard | 2.128–2.2223 EUR | Oct 10, 2026 |
| Alexandre Fraichard | 2.3425–2.36 EUR | Sep 29, 2026 |
| Alexandre Fraichard | 2.4919–2.5 EUR | Jul 27, 2026 |
Model details
Cluster breakdown (does not change the score)
- 15-day buyer breadth (count)
- 1 distinct reported filers
- Peak time window
- 2026-05-28 to 2026-05-28
- Current breadth input
- 0.300 (capped at 4+ buyers)
- Buyer independence
- Not yet measured; related-party fields are not cross-market comparable
What the filings show
- 🟢 Recent eligible purchase
Alexandre Fraichard · 30k EUR · Price 2.128–2.2223 EUR · Oct 10, 2026 - 🟢 Eligible purchase
Alexandre Fraichard · 190k EUR · Price 2.3425–2.36 EUR · Sep 29, 2026 - 🟢 Large eligible purchase
Alexandre Fraichard · 89k EUR · Price 2.4919–2.5 EUR · Jul 27, 2026 - 🟡 2 remaining qualified transaction line(s) across 2 disclosure(s)
- 🔴 4 other transaction line(s) are not counted as discretionary-buying evidence; 0 have zero price
Insider vs stock price
5 purchase day(s), 15 purchase line(s) in the 180-day window. 2 sale day(s), 4 sale line(s).
Daily close (EUR)Day with an insider purchaseDay with an insider sale
Markers sit on the closing price of the transaction day. They show when insiders traded, not the price they paid or received. "Since" compares that day's close with the last close shown; it is what happened at this company, not a forecast.
If you had followed the purchase
Each row starts on the first close on or after the day a purchase was made public, the earliest a reader could have acted, and ends on the last close shown above.
| Made public | Insiders | In this stock, now | In the median peer stock, now | Difference |
|---|---|---|---|---|
| 2026-06-22 | 1 | 1,000 +0.0% | 939 −6.1% | +61 +6.1 pts |
| 2026-07-20 | 1 | 968 −3.2% | 917 −8.3% | +51 +5.1 pts |
| 2026-07-29 | 1 | 968 −3.2% | 893 −10.7% | +75 +7.5 pts |
| 2026-09-30 | 1 | 1,026 +2.6% | 980 −2.0% | +45 +4.5 pts |
4 of 4 disclosure day(s) ended ahead of the median peer stock.
Close to close, before costs, taxes, dividends and currency moves. The peer is the median of the other stocks on the same exchange for which this site holds prices (103 here), not an index. This is what happened, not a forecast: across all purchases on this site the typical gap is close to zero.
Insider timeline
2 insiders bought in the last 180 days, 1 of them more than once. 1 of the buyers also disclosed a sale in the window.
Tap an item for what it means.
●A purchase: the bigger the dot, the more was bought
Each dot is one insider's purchases on one day. The dot's area follows the amount: the largest purchase here gets the largest dot. Hold the pointer over a dot to see the date and the amount.
×A sale
A cross is one insider's sales on one day. People sell to pay tax, to cash in share awards or to hold less of one company, so a sale says less than a purchase does. When someone bought and sold on the same day, the cross sits beside the dot. The totals are under “Purchases against sales” below.
Blue line: this share's price, −4.0% over these six months
The closing price of each day, from 2.50 on 2026-04-21 to 2.40 on 2026-10-07. The line has no scale; read it for high and low: a dot on a low stretch was bought cheaply, a dot on a high stretch was not.
Dashed line: the typical stock on the same exchange, −10.7%
Taken from the 104 other stocks on the same exchange that this site holds prices for. Each is measured from the first day of the window, and every day the middle one is drawn. It starts where the blue line starts, so the gap between the two is the difference: this share −4.0%, the typical one −10.7%, 6.7 points ahead. It is not an index and not a comparison within one industry.
▂Grey bars: companies across Europe disclosing purchases each week
A taller bar is a week in which more companies disclosed insider purchases.
This company: insiders buying per month, last 12 months
Nov
2Dec
Jan
Feb
Mar
Apr
1May
Jun
1Jul
Aug
1Sep
1Oct
Darker bars are inside the 180-day window above.
Who traded
| Insider | Role | Purchases | Sales | Bought | First purchase | Share price since | Earlier purchases |
|---|---|---|---|---|---|---|---|
| JEAN LOUIS MENARD | Board member | — | 1 | — | — | — | fewer than 5 completed |
| SOLYS SARL | Board member | 1 | 1 | 12.0k EUR | 2026-05-28 | +0.0% | fewer than 5 completed |
| CARLYS SOCIETE CIVILE | Board member | — | 1 | — | — | — | fewer than 5 completed |
| ISTYA FOND DE DOTATION | Board member | — | 1 | — | — | — | fewer than 5 completed |
| Alexandre Fraichard | Role not classified | 4 | — | 370.0k EUR | 2026-07-16 | −8.0% | fewer than 5 completed |
Purchases against sales
Purchases87%382.0k EUR · 15 line(s) · 2 insider(s)
Sales13%57.2k EUR · 4 line(s) · 4 insider(s)
Shares of the reported value of insider transactions in the 180-day window. Sales include disposals for tax, at option exercise or under a pre-set plan, which say little about an insider's view. The split describes what was disclosed; it is not a signal.
Why this score? · Model details
Priority = 100 × Σ(fixed weight × 0–1 rule-based input)
| Factor | Weight | This company input | Point contribution |
|---|---|---|---|
| 15-day buyer breadth (count) | 35% | 0.300 | 10.5 |
| Qualified-buy size | 25% | 0.823 | 20.6 |
| Role informativeness (inverted) | 20% | 0.350 | 7.0 |
| Recency | 10% | 0.616 | 6.2 |
| Buy/sell conviction | 10% | 0.870 | 8.7 |
This is a heuristic ordering under the current rules, not a calibrated return forecast. It explains why candidates rank differently; the public-filing evidence and data limits are shown below.
BULL VS BEAR
Two readings of this buying
The same filings, read two ways. Each line is a fact stored for this company with the number behind it, and appears only when that number crosses a fixed threshold. Neither side is a forecast and no winner is declared.
Since 2026-10-13, neither column has changed. All bull and bear lists, and what followed each line in the past →
Where the evidence comes from
Independent evidence does not object: the purchases themselves carry bull lines (large purchases, bought in the last two weeks); share price and trading, short sellers, company results were checked and none crosses a bear threshold. No data is held for: company actions.
- The insider purchases themselvesBulllarge purchases, bought in the last two weeks Bearvalue concentrated in one buyer, usual level for this company3 checked, under the threshold · 3 missing
- Share price and trading2 checked, under the threshold
- Short sellers1 checked, under the threshold
- Company results1 checked, under the threshold · 1 missing
- Company actionsno data held
Bull case · the buying is informative
- Net purchases of €324k equal 1.1% of the company's market value (€28.9M): large for the size of the business.
- The latest purchase is 7 days old (2026-10-10). The buying is current, not left over from an earlier quarter.
Bear case · discount it
- Alexandre Fraichard accounts for 97% of the value bought. The other 1 buyer adds names more than money.Record: after 3,396 earlier disclosures like this, the median 60-session excess return was −3.4%, within 1 percentage point of all comparable disclosures (−3.5%).
- Buying at this level is normal here: 2 insiders bought in the previous 180 days and 2 in this one.Record: after 2,869 earlier disclosures like this, the median 60-session excess return was −2.6%, within 1 percentage point of all comparable disclosures (−2.7%).
Evidence still missing
- No buyer here has 5 or more completed earlier purchases on record, so there is no track record to weigh.
- Only one reading of profitability is held (profit margin 3.6%). Whether earnings and cash flow are rising or falling needs the last two reports side by side.
- European notifications have no field saying whether a purchase was pre-arranged; there is no counterpart to the US 10b5-1 box. None of the 15 purchase lines mentions a plan, but a bare “Acquisition” does not rule one out.
- The filings give the size of each trade, not what the buyer already held. Whether a purchase added 1% to a personal stake or doubled it is not known.
Checked and under the threshold: 7
- BullAt most 1 insider bought within any 15 days. Counted for the bull side from 3.
- Bear0 of 2 buyers filed as a person closely associated with a manager. Counted for the bear side from half.
- BearInsiders sold €57k in the same 180 days, 15% of the amount bought. Counted for the bear side from 25%.
- BearThe share price changed −10% over six months (three months −14%, one month −8.2%) and stands 22% below its 52-week high. Counted for the bear side from a fall of 20%.
- BearOver three months the share price changed −14% and the median of 271 Healthcare companies changed −6.3%: behind by 8 points. Counted for the bear side from 20 points behind.
- BearThe register of AMF shows no published net short position in this company. Positions under 0.5% are never published, so this does not show that nobody is short.
- BearProfit margin on the latest captured figures is 3.6%. Counted for the bear side when negative.
Both columns arrange stored facts only. They do not change the insider score or the ranking and are not investment advice.
Signal history
52.9 / 100
Latest recorded score
↑ +9.0 ptsversus the comparable snapshot on 2026-09-14 (34 calendar days apart)
- Recorded snapshots
- 35
- First snapshot
- 2026-08-26
Only scores captured when the scoring run completed are compared. These are raw signal scores saved when each full scoring run completed. They describe changes in research ranking, not price performance or returns.
Why did it change?
Decomposition across the five score factors between comparable snapshots; historical scores are not recalculated.
- Purchase size+1.8 pts
- Recency+5.8 pts
- Conviction+1.3 pts
Signal score history
Fixed 0–100 scale; dates are spaced by calendar time.
Recent recorded points
- 47.1
- 44.1
- 43.7
- 52.3
- 52.9
View all recorded scores
| Snapshot date | Signal score |
|---|---|
| 2026-08-26 | 47.1 |
| 2026-08-27 | 47.1 |
| 2026-08-28 | 44.7 |
| 2026-08-31 | 44.5 |
| 2026-09-01 | 44.4 |
| 2026-09-02 | 44.4 |
| 2026-09-03 | 44.3 |
| 2026-09-04 | 44.3 |
| 2026-09-07 | 44.1 |
| 2026-09-08 | 44.1 |
| 2026-09-09 | 44.1 |
| 2026-09-10 | 44.0 |
| 2026-09-11 | 44.0 |
| 2026-09-14 | 43.9 |
| 2026-09-23 | 43.8 |
| 2026-09-24 | 43.8 |
| 2026-09-25 | 43.8 |
| 2026-09-28 | 43.7 |
| 2026-09-29 | 43.7 |
| 2026-09-30 | 43.7 |
| 2026-10-01 | 55.2 |
| 2026-10-02 | 54.6 |
| 2026-10-03 | 54.6 |
| 2026-10-04 | 54.6 |
| 2026-10-05 | 53.1 |
| 2026-10-06 | 52.7 |
| 2026-10-07 | 52.3 |
| 2026-10-08 | 51.9 |
| 2026-10-09 | 51.5 |
| 2026-10-12 | 50.6 |
| 2026-10-13 | 54.9 |
| 2026-10-14 | 54.3 |
| 2026-10-15 | 53.8 |
| 2026-10-16 | 53.4 |
| 2026-10-18 | 52.9 |
Sector context
- Buying breadth
- 6.1% (48 / 792 issuers)
- Sector rank
- #11 / 12
- 7D breadth change
- -0.4 pp · vs 2026-10-12 (6d)
- 30D breadth change
- History building
This is sector-level research context. It does not affect the Insider Signal or ranking.
Insider profile outcomes
Historical performance following insider filings. The company role is translated below each name while preserving the original title.
- Excess return = stock return − CAC 40 return over the same period.
- Hit rate = completed events with positive excess return ÷ total completed events.
- Price coverage = valid point-in-time prices ÷ events mature enough for that period.
- Returns start on the first shared trading session on or after publication.
- Small-sample rule: n<5 is shown for transparency and is not scored.
Events are disclosure-level observations; related disclosures published on the same date may share a return path and may not be statistically independent. This research enrichment does not affect the insider score or ranking.
| Period | Completed events | Price coverage | Hit rate | Median excess return | Average excess return | Worst excess return |
|---|---|---|---|---|---|---|
| 5D | 1Small sample | 100.0% (1/1) | 0.0% (0/1) | -3.3% | -3.3% | -3.3% |
| 20D | 1Small sample | 100.0% (1/1) | 100.0% (1/1) | +4.9% | +4.9% | +4.9% |
| 60D | 1Small sample | 100.0% (1/1) | 100.0% (1/1) | +10.0% | +10.0% | +10.0% |
| 120D | 1Small sample | 100.0% (1/1) | 0.0% (0/1) | -7.7% | -7.7% | -7.7% |
| Period | Completed events | Price coverage | Hit rate | Median excess return | Average excess return | Worst excess return |
|---|---|---|---|---|---|---|
| 5D | 1Small sample | 100.0% (1/1) | 100.0% (1/1) | +2.7% | +2.7% | +2.7% |
| 20D | 1Small sample | 100.0% (1/1) | 0.0% (0/1) | -0.5% | -0.5% | -0.5% |
| 60D | 1Small sample | 100.0% (1/1) | 100.0% (1/1) | +0.8% | +0.8% | +0.8% |
| 120D | 1Small sample | 100.0% (1/1) | 0.0% (0/1) | -14.4% | -14.4% | -14.4% |
Market context
PRICE PERFORMANCE
VOLATILITY & LIQUIDITY
- Volatility
- 40.8%
- Beta
- 0.37
- Avg daily volume
- €17,823.7
VALUATION
- Market cap
- €28.9M
- P/E
- —
FUNDAMENTALS
- Profit margin
- 3.6%
- ROE
- 4.3%
- Industry
- Biotechnology
Prices to 14 Oct 2026: OpenBB/yfinance. From OpenBB/yfinance, captured 14 Oct 2026: Market cap, Profit margin, ROE, Beta, Industry. It does not affect the insider score or rank.
Disclosed net short positions
The AMF register, read 18 Oct 2026, publishes no net short position of 0.5% or more in this issuer. Positions below 0.5% are never published, so this is not evidence that nobody is short.
Short-position disclosures are external context; they do not affect the insider score, ranking, or filing eligibility.
Insiders' buying price vs the latest close
The latest close in the price history is more than a week old.
Buying size vs market trading
Market history is too old for this snapshot; ratios are withheld.
Market-data coverage: 249 verified sessions · Latest session: 2026-10-07 · Ratio status: Unavailable
Traded value is estimated as close × shares traded, in major currency units. Includes disclosed qualifying purchases; disclosures may lag. Contractual or planned acquisitions are not necessarily discretionary. Ratios describe relative trading size, not market participation or score contributions.
Latest news
No news has been captured for this company.
Regulatory filings
The filing records held for this company carry no link to the original notice.
Filing evidence
These are underlying national-feed records from the 365-day window ending on the saved ranking snapshot. The score uses only the latest 180 days; older qualifying equity purchases remain visible for audit but do not enter the current score. The original filer, role, transaction classification, instrument, price, volume, value and source fields are retained. The first three rows are shown; remaining records can be unfolded for audit. Other transaction types are retained but excluded from the score.
Excluded transactions & classification
17 qualifying purchase disclosure(s) · 17 transaction line(s)
Oct 10, 2026Acquisition
Alexandre Fraichard · DG
Action · 5525.0000 shares × 2.1280 EUR · —
Oct 10, 2026Acquisition
Alexandre Fraichard · DG
Action · 914.0000 shares × 2.2223 EUR · —
Oct 10, 2026Acquisition
Alexandre Fraichard · DG
Action · 1979.0000 shares × 2.2133 EUR · —
Unfold all 14 remaining filing row(s)
| Transaction date | Published | Filer | Role | Transaction | Instrument | Price (local currency) | Quote currency | Volume | Source |
|---|---|---|---|---|---|---|---|---|---|
| 2026-10-10 | 2026-10-12 | Alexandre Fraichard | DG | Acquisition | Action | 2.1744 EUR | EUR | 5332.0000 | — |
| 2026-09-29 | 2026-09-30 | Alexandre Fraichard | DG | Acquisition | Action | 2.3600 EUR | EUR | 3149.0000 | — |
| 2026-09-29 | 2026-09-30 | Alexandre Fraichard | DG | Acquisition | Action | 2.3436 EUR | EUR | 34699.0000 | — |
| 2026-09-29 | 2026-09-30 | Alexandre Fraichard | DG | Acquisition | Action | 2.3549 EUR | EUR | 30677.0000 | — |
| 2026-09-29 | 2026-09-30 | Alexandre Fraichard | DG | Acquisition | Action | 2.3425 EUR | EUR | 12474.0000 | — |
| 2026-07-27 | 2026-07-29 | Alexandre Fraichard | DG | Acquisition | Action | 2.4969 EUR | EUR | 12905.0000 | — |
| 2026-07-27 | 2026-07-29 | Alexandre Fraichard | DG | Acquisition | Action | 2.5000 EUR | EUR | 3327.0000 | — |
| 2026-07-27 | 2026-07-29 | Alexandre Fraichard | DG | Acquisition | Action | 2.4919 EUR | EUR | 4580.0000 | — |
| 2026-07-27 | 2026-07-29 | Alexandre Fraichard | DG | Acquisition | Action | 2.4950 EUR | EUR | 12188.0000 | — |
| 2026-07-27 | 2026-07-29 | Alexandre Fraichard | DG | Acquisition | Action | 2.4981 EUR | EUR | 2850.0000 | — |
| 2026-07-16 | 2026-07-20 | Alexandre Fraichard | DG | Acquisition | Action | 2.4200 EUR | EUR | 25000.0000 | — |
| 2026-05-28 | 2026-06-22 | SOLYS SARL | ADMINISTRATEUR | Acquisition | Action | 2.4000 EUR | EUR | 5000.0000 | — |
| 2025-12-17 | 2025-12-23 | JEAN LOUIS MENARD | ADMINISTRATEUR | Acquisition | Action | 2.3500 EUR | EUR | 38500.0000 | — |
| 2025-12-17 | 2025-12-19 | olivier Charmeil | Administrateur Indépendant | Souscription | Action | 2.3500 EUR | EUR | 42553.0000 | — |
Showing 17 of 17 matching raw-feed row(s) from the current 365-day research window. Prices and reported values remain in the filing currency and its major unit (for example, UK pence are parsed as GBP). The screen-level € aggregate is separately FX-normalised for research ranking, not a trade-date conversion.
Other disclosed transactions · excluded from score
View 4 other transaction(s)
Jun 17, 2026Cession
CARLYS SOCIETE CIVILE · ADMINISTRATEUR
Action · 10000.0000 shares × 2.4000 EUR · —
Jun 17, 2026Cession
SOLYS SARL · ADMINISTRATEUR
Action · 4900.0000 shares × 2.4000 EUR · —
Jun 17, 2026Cession
ISTYA FOND DE DOTATION · ADMINISTRATEUR
Action · 4870.0000 shares × 2.4000 EUR · —
Unfold all 1 remaining filing row(s)
| Transaction date | Published | Filer | Role | Transaction | Instrument | Price (local currency) | Quote currency | Volume | Source |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-28 | 2026-05-29 | JEAN LOUIS MENARD | ADMINISTRATEUR | Cession | Action | 2.4000 EUR | EUR | 4044.0000 | — |
Showing 4 of 4 matching raw-feed row(s) from the current 365-day research window. Prices and reported values remain in the filing currency and its major unit (for example, UK pence are parsed as GBP). The screen-level € aggregate is separately FX-normalised for research ranking, not a trade-date conversion.
Snapshot & identity
- Snapshot date
- 2026-10-18
- Ticker
- ALGEN.PA
- ISIN
- FR0004053510
- Sector
- Healthcare
- Industry
- Biotechnology
Company logos by Parqet